An FDA inspection of the Zhejiang Huahai Pharmaceutical plant a year ahead of its global recall of tainted valsartan found big problems.

Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.

Kyowa is also testing the drug in early-phase trials for solid tumors, in combo with its own IDO inhibitor KHK2455, BMS’ Opdivo and AZ’s Imfinzi.

Samsung BioLogics is slated to get a piece of the $22 billion investment Samsung says it will invest in growth businesses.

A blockchain-based drug and vaccine traceability system, which the developer says records all data in the vaccine supply chain, will debut in Shanghai.

Multinational pharma companies have all together closed 16 manufacturing plants in South Korea over the past 20 years, local media reports.

The sale gives Dendreon better access to capital for expansion and deals, its top executive said—perhaps into CAR-T or other cell therapies, an area where the…

Shire could fill Takeda's gap of late-stage assets; GSK lays off 1,000 as a Bangladesh plant nears closure; Laekna gets two Novartis cancer drugs.